Developing a diagnostic model for pancreatic cystic tumors using fluid samples

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify molecular diagnostic markers for pancreatic cystic tumors by analyzing cystic fluid samples from patients. It involves cfDNA methylation sequencing and proteomic assays to differentiate between benign and malignant tumors, as well as mucinous and non-mucinous types. Participants will provide post-operative cyst fluid specimens, which will be analyzed to correlate molecular features with pathological characteristics and malignancy levels. The study seeks to construct a more effective diagnostic model through multi-omics analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects are ≥ 18 years old, regardless of gender;
* Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;
* Subjects voluntarily accepted radical resection of pancreatic cystic tumors;
* Subjects or family members voluntarily sign the informed consent form for clinical research.

Exclusion Criteria:

* The excised sample does not contain cystic components, or the cystic fluid cannot be collected;
* Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;
* Receive antibiotic treatment within 1 week before operation;
* Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;
* The subjects or their families refused to sign the informed consent form for clinical research.

Where it's running

• Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Shiyu Li — Changhai Hospital
• Study coordinator: Kaixuan Wang
• Email: lizfish@126.com
• Phone: 021-31166666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

• Methylation markers from saliva to guide lung cancer screening

  This study tests whether DNA methylation patterns in saliva can more accurately identify people who should get a low-dose CT scan for lung cancer screening.

  Recruiting University Hospital, Antwerp · Antwerp, Antwerpen · NCT07631624

• Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes

  This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07608055

• Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay

  This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.

  Recruiting at 69 sites Cosomil, Inc. · Nagakute, Aichi-ken and 68 other locations · NCT07605819

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.